FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesNavigating Regulatory and QA Challenges in Clinical Supply Management
Topic: Regulatory
Executive Summary
Members
EAP 105: Expanded Access Logistics
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Presentation
Members
GDPR Considerations for DtP Supply Chains
Topics: Regulatory, Supply Chain
Guidance Document
Free
